Work

Preclinical Pharmacological and Toxicological Evaluation of SB5794, a Novel Aryl Hydrocarbon Receptor Modulator on the Kynurenine–AhR Axis

Year: 2025

Type: article

Abstract: AhR antagonistic activity. In syngeneic tumor models, SB5794 significantly inhibited tumor growth, and its combination with anti-PD-1 therapy further enhanced antitumor efficacy. However, repeated-dose studies revealed dose-dependent histopathological changes in the gastrointestinal tract, liver, and immune organs. Collectively, these findings demonstrate that SB5794 possesses improved drug-like properties and strong immunomodulatory activity, supporting its potential as a next-generation AhR-targeted immunotherapeutic candidate.

Source: Biomolecules & Therapeutics

DOI: 10.4062/biomolther.2025.230

Authors: Daewon Cha, Soo-Jung Choi, Hyunwoo Park, Dae Young Lee, Min Sung Joo, Wonhyung Lee, Jungsang Park, Eunhye Lee, Hakwon Kim

Institutions: Kyung Hee University, Dong-A ST (South Korea), Daegu-Gyeongbuk Medical Innovation Foundation

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7119112613

FWCI: 0.373

Cites:

Cited by: 1

Related to: